Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Study Type
OBSERVATIONAL
Enrollment
121
50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
Pfizer Investigational Site
Banská Bystrica, Slovakia
Pfizer Investigational Site
Bojnice, Slovakia
Pfizer Investigational Site
Bratislava, Slovakia
Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib
Time frame: 36 months
Dose modifications
Time frame: 36 months
Incidence of new diagnosed hypertension
Time frame: 36 months
Incidence of new diagnosed hypothyroidism
Time frame: 36 months
Safety of sunitinib malate in "real-life" setting
Time frame: 36 months
Efficacy of sunitinib malate in "real-life" setting
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Bratislava, Slovakia
Pfizer Investigational Site
Košice, Slovakia
Pfizer Investigational Site
Michalovce, Slovakia
Pfizer Investigational Site
Nitra, Slovakia
Pfizer Investigational Site
Poprad, Slovakia
Pfizer Investigational Site
Prešov, Slovakia
Pfizer Investigational Site
Ružomberok, Slovakia
...and 4 more locations